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Abstract 
We aimed to investigate a novel and uncharacterised E3 ubiquitin ligase in skeletal muscle atrophy, recovery 
from atrophy/injury, anabolism and hypertrophy. We demonstrated an alternate gene expression profile for 
UBR5 versus well characterised E3-ligases, MuRF1/MAFbx, where after atrophy evoked by continuous-low-
frequency electrical-stimulation in rats, MuRF1/MAFbx were both elevated yet UBR5 was unchanged. 
Furthermore, after recovery of muscle mass post tetrodotoxin (TTX) induced-atrophy in rats, UBR5 was 
hypomethylated and increased at the gene expression level, while a suppression of MuRF1/MAFbx was 
observed. At the protein level, we also demonstrated a significant increase in UBR5 after recovery of muscle 
mass from hindlimb unloading in both adult and aged rats, and after recovery from atrophy evoked by nerve 
crush injury in mice. During anabolism and hypertrophy, UBR5 gene expression increased following acute 
loading in three-dimensional bioengineered mouse muscle in-vitro, and after chronic electrical-stimulation-
induced hypertrophy in rats in-vivo, without increases in MuRF1/MAFbx. Additionally, UBR5 protein 
abundance increased following functional overload-induced hypertrophy of the plantaris muscle in mice and 
during differentiation of primary human muscle cells. Finally, in humans, genetic association studies 
(>700,000 SNPs) demonstrated that the A alleles of rs10505025 and rs4734621 SNPs in the UBR5 gene 
were strongly associated with larger cross-sectional area of fast-twitch muscle fibres and favoured 
strength/power versus endurance/untrained phenotypes. Overall, we suggest that UBR5 is a novel E3 
ubiquitin ligase that is inversely regulated to MuRF1/MAFbx, is epigenetically regulated, and is elevated at 
both the gene expression and protein level during recovery from skeletal muscle atrophy and hypertrophy.  
 
Key Points:  
• We have recently identified that a HECT domain E3 ubiquitin ligase, named UBR5, is altered 
epigenetically (via DNA methylation) after human skeletal muscle hypertrophy, where its gene expression 
is positively correlated with increasing lean leg mass after training and retraining. 
• In the present study we extensively investigate this novel and uncharacterised E3 ubiquitin ligase (UBR5) 
in skeletal muscle atrophy, recovery from atrophy and injury, anabolism and hypertrophy. 
• We demonstrated that UBR5 was epigenetically via altered DNA methylation during recovery from 
atrophy. 
• We also determined that UBR5 was alternatively regulated versus well characterised E3 ligases, 
MuRF1/MAFbx, at the gene expression level during atrophy, recovery from atrophy and hypertrophy.  
• UBR5 also increased at the protein level during recovery from atrophy and injury, hypertrophy and during 
human muscle cell differentiation.  
• Finally, in humans, genetic variations of the UBR5 gene were strongly associated with larger fast-twitch 
muscle fibres and strength/power performance versus endurance/untrained phenotypes. 
 
Keywords: UBR5, EDD1, DNA methylation, E3 ubiquitin ligase, hypertrophy, atrophy, muscle recovery, 
epigenetics, remodelling, TTX-atrophy, hindlimb suspension, functional overload, synergist ablation, 
functional-overload, gene expression, pyrosequencing, bioengineered muscle, mechanical loading.  
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Introduction 
Proteolysis is the breakdown of proteins within cells. The ubiquitin-proteasome is the main system involved 
in protein turnover (Rock et al., 1994; Cao et al., 2005). In skeletal muscle, this system increases protein 
degradation as it reduces in size (reviewed in (Bodine & Baehr, 2014)) and remodels (Yang et al., 2006; 
Gomes et al., 2012; Slimani et al., 2012). Ubiquitin-mediated proteolysis operates via distinctive enzymatic 
tagging to an area of a polypeptide chain using ubiquitin, securing the substrate proteins fate for degradation 
in the proteasome (Glickman & Ciechanover, 2002). Proteins tagged with ubiquitin are then recognised by 
the large 26S protease complex that degrades them into smaller peptides (Baumeister et al., 1998). This 
ubiquitination tagging system is activated by enzymes triggered sequentially. The E1 enzyme activates 
ubiquitin, the E2 enzyme carries and conjugates ubiquitin to the E3 enzyme that then catalyses its binding to 
the designated protein substrate for degradation (reviewed in (Metzger et al., 2012)). There are approximately 
40 E2 and over 600 E3 ubiquitin ligases in the human genome making it an extremely complex and relatively 
uncharacterised system.  
 
Over the past two decades, the E3 ligases in particular have received specific attention in skeletal muscle, 
namely due to the discovery of important E3’s that are selectively expressed in this tissue, including: Trim63, 
renamed muscle specific RING finger protein 1 (MuRF1); Fbxo32, renamed the F-box containing ubiquitin 
protein ligase atrogin-1 or Muscle Atrophy F-box (MAFbx/Atrogin-1) (Bodine et al., 2001; Gomes et al., 2001). 
As well as the more recently characterised; Fbxo30, renamed muscle ubiquitin ligase of SCF complex in 
atrophy-1 (MUSA1) (Sartori et al., 2013), Parkin and ZNF216 (Hishiya et al., 2006; Furuya et al., 2014). 
MuRF1 contains a RING finger domain, whereas MAFbx/Atrogin-1 and MUSA1 have an F-box domain (part 
of the SCF family of E3s). RING fingers form the vast majority of all the E3 ligases. RING finger domains are 
zinc-binding motifs of 40-60 histidine and cysteine amino acid residues in a C3HC4 (RING) or C3H2C3 (RING-
H2) formation (Bordone & Freemont, 1996). E3 RING finger proteins cause ubiquitin to be catalysed 
indirectly, acting as a scaffold that brings E2 proteins together with the substrate (Lorick et al., 1999; Metzger 
et al., 2012). Importantly, E3 ligases MuRF1 and MAFbx/Atrogin-1 have been demonstrated to increase 
rapidly at the gene expression level at around 48 hrs in the time course of atrophy in rodents following disuse 
(e.g. after denervation, hindlimb unloading, tetrodotoxin nerve exposure) increasing progressively up to 7-10 
days (Bodine et al., 2001; Gomes et al., 2001; Clavel et al., 2006; Moresi et al., 2010; Fisher et al., 2017). 
Furthermore, the expression of these genes increased in human muscle 48 hrs after spinal cord injury and 
14 days after limb immobilisation (de Boer et al., 2007; Urso et al., 2007; Gustafsson et al., 2010). MuRF1 
and MAFbx/Atrogin-1 have also been shown to increase after starvation induced skeletal muscle atrophy 
(Gomes et al., 2001; Lecker et al., 2004) and are elevated in aging and cachexia (Gomes et al., 2001; Lecker 
et al., 2004; Clavel et al., 2006; Costelli et al., 2006; Raue et al., 2007; Altun et al., 2010). MuRF1 has been 
suggested to target myofibrillar proteins such as titin, nebulin, troponin1 (Witt et al., 2005) and thick filament 
proteins such as myosin-binding protein C (MyBP-C) as well as myosin light chains 1 and 2 (MyLC1 and 
MyLC2) for degradation (Cohen et al., 2009), whereas suggested MAFbx substrates include the myogenic 
regulatory factor, MyoD, Myogenin, eukaryotic translation initiation factor 3 subunit f (eIF3-f) (Tintignac et al., 
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2005; Lagirand-Cantaloube et al., 2008; Jogo et al., 2009) and the intermediate filament proteins vimentin 
and desmin (Lokireddy et al., 2012). Importantly, knock-down of MuRF1 and MAFbx/Atrogin-1 enzymes 
render mice partially resistant to denervation induced atrophy (Bodine et al., 2001), and MuRF1 knock 
down also prevents atrophy following hindlimb unloading (HU) and glucocorticoid treatment (Bodine et al., 
2001; Labeit et al., 2010; Baehr et al., 2011). MuRF1 knock-down can help delay anabolic resistance and 
maintain muscle mass in aged rodents (Hwee et al., 2014). Finally, MUSA1 knockdown using in-vivo 
electroporation of shRNA has been shown to spare muscle mass following denervation and prevent more 
severe atrophy observed in Smad4−/− mice (Sartori et al., 2013). Collectively, these data confirming an 
important function for these E3’s in skeletal muscle atrophy.  
 
Together with RING finger domains, another key group of the E3 enzymes contain HECT (homologous to 
E6-AP carboxy-terminus) domains. The HECT domain of these E3 enzymes, unlike RING finger family 
members, directly binds activated ubiquitin to the target protein substrate. However, HECT domain E3 ligases 
remain relatively unstudied in skeletal muscle atrophy or remodelling. Interestingly, we have recently 
demonstrated that a HECT domain E3 ligase called UBR5 (aka. EDD1), previously uncharacterized in 
skeletal muscle, is an epigenetically regulated gene (identified using 850K DNA methylation arrays) 
hypomethylated after resistance exercise-induced muscle hypertrophy in humans (termed loading/training) 
(Seaborne et al., 2018b). In this study, resistance exercise-induced hypertrophy was followed by complete 
cessation of exercise and a return of lean leg mass to pre-exercise baseline levels (unloading/detraining). In 
the same participants, a second period of resistance exercise-induced hypertrophy (reloading/retraining) 
ensued, in which the greatest increase in lean leg mass was observed. At the DNA level, we discovered that 
UBR5 became hypomethylated during periods of resistance exercise induced hypertrophy and returned to 
baseline levels upon exercise cessation. This oscillating methylation profile was inversely associated with 
changes in UBR5 expression, suggesting that the transcript was epigenetically regulated. Importantly, the 
largest increases in hypomethylation, gene expression and muscle mass were observed after later 
reloading/retraining. Therefore, the level of UBR5 gene expression was positively and strongly correlated 
with the increases in lean leg mass across after training and retraining (Seaborne et al., 2018b). This data 
indicated that UBR5 was an E3 ligase associated with muscle hypertrophy rather than muscle atrophy. This 
was surprising given the well-defined role of the aforementioned E3 ligases in protein degradation, and 
therefore suggested that UBR5 may instead be important in muscle remodelling and recovery during changes 
in muscle mass. We therefore aimed to investigate the role of UBR5 more extensively during atrophy/injury 
and recovery from atrophy/injury as well as following anabolism, hypertrophy and muscle cell differentiation 
in order to start to characterise its role across these processes. We also aimed to further substantiate UBR5’s 
genetic role in muscle fibre size and physical performance using micro-array analysis in humans.  
 
Methods 
 
Tetrodotoxin (TTX)- induced atrophy and TTX cessation for recovery in-vivo 
In new analysis of samples derived from previous work carried out by our group (Fisher et al., 2017), we 
assessed UBR5 DNA methylation and gene expression following tetrodotoxin (TTX) induced atrophy and 
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recovery of the tibialis anterior (TA) in rats. Briefly, under anaesthesia with isoflurane and buprenorphine, the 
common peroneal nerve in the left hindlimb of adult male Wistar rats was exposed to TTX using an implanted 
subcutaneous mini-osmotic pump (Mini Osmotic Pump 2002, Alzet, Cupertino CA, USA) in the scapular 
region, with a delivery tube leading to a silicone rubber cuff placed around the nerve. This delivered 0.5 μl/hr 
of TTX (350 μg/ml in sterile 0.9 % saline) so that the ankle dorsiflexor muscles (TA and extensor digitorum 
longus/EDL) were silenced but normal voluntary plantar-flexion was maintained for a period of 14 days (d). 
This evoked reductions in muscle weight of 7, 29 and 51% and fiber CSA of 18, 42, 69% at 3, 7 and 14 d 
respectively (Fisher et al., 2017). The muscle was then allowed to recover after exhaustion in osmotic pump 
delivery of TTX to the peroneal nerve and allowing normal habitual physical activity to resume for a period 7 
days post 14 d TTX atrophy (recovery), that resulted in a 52 and 63% increase after 7 d recovery of muscle 
weight and fiber CSA respectively versus the 14 d TTX-induced atrophy timepoint (Fisher et al., 2017). RNA 
and DNA were isolated from the contralateral control (right) limb and from the TTX (left) limb at 3, 7, 14 d (n 
= 6 for 3/7/14 d, n = 4 recovery). Experimental procedures were conducted according to the permissions 
within a project license granted under the British Home Office Animals (Scientific Procedures) Act 1986. 
Wistar rats were sourced from registered breeding colonies at LJMU Life Sciences Support Unit and 
euthanasia was conducted by rising CO2 followed by cervical dislocation. 
 
Atrophy induced via continuous low frequency electrical stimulation in-vivo 
In male Wistar rats (3 months of age) under anaesthesia with isoflurane and buprenorphine, a sterilised 
miniature implantable stimulator was inserted into the abdominal cavity and sutured to the abdominal wall, in 
a model previously described (Jarvis et al., 1996). Briefly, in new experimentation, the electrodes were 
tunnelled subcutaneously and placed under (but not touching) the common peroneal nerve and sutured to 
the aponeurosis of the gastrocnemius muscle of the left hind limb to keep the electrodes in place, and allow 
activation of the TA and EDL via the common peroneal nerve. Animals were then allowed to recover from 
the implant procedure for 7 d before initiating a continuous low frequency 20 Hz stimulation for a further 
period of 7 d, turned on remotely using a stroboscope to transmit a sequence of light pulses through the skin. 
This resulted in an 12.64% reduction in muscle weight of the TA after 7 d in the stimulated versus the 
contralateral unstimulated right control limb (n = 6 muscle weight, Figure 1A), using methodology previously 
described (Jarvis et al., 1996). Daily stimulation was conducted under no anaesthesia and amplitude of nerve 
stimulation was remotely adjusted under careful observation to provide motor-neurone activation without limb 
withdrawal or signs of distress. TA samples were taken from the stimulated and unstimulated contralateral 
limb at the end of the 7 d stimulation protocol. Experimental procedures were conducted according to 
permissions within a project license granted under the British Home Office Animals (Scientific Procedures) 
Act 1986. Wistar rats were sourced from registered breeding colonies at LJMU Life Sciences Support Unit 
and euthanasia was conducted by rising CO2 followed by cervical dislocation. 
 
Hindlimb suspension induced-atrophy and recovery in adult and aged animals in-vivo 
The response of hindlimb muscles to unloading and recovery was studied in 9-month (adult) and 29-month 
(aged) male Fischer 344-Brown Norway (F344BN) rats obtained from the National Institute of Aging. Using 
the same samples obtained from previous published experiments (Baehr et al., 2016), we undertook new 
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analysis of UBR5 protein abundance. Briefly, hindlimb unloading (HU) was achieved by tail-suspension as 
previously described (Thomason et al., 1987; Baehr et al., 2016), with the rats attached to a swivel (360° 
rotation) mounted plastic bar at the top of the cage in a ∼30° head-down tilt position for a period of 14 d. 
Animals were released from the tail suspension on day 15 at which time the rats were individually housed 
and allowed unrestricted cage activity for 3, 7, or 14 days (n = 6/ group). Muscle from the medial 
gastrocnemius (MG) was removed and lysed for protein extraction at baseline, 14 d after HU and at 3, 7 and 
14 d of reloading/recovery (REL). During tissue collection, animals were anesthetized with isoflurane on 
completion of tissue removal, rats were euthanized by exsanguination. All animal procedures were approved 
by the Institutional Animal Care and Use Committee at the University of California, Davis, USA.  
 
Nerve crush injury, atrophy and recovery in-vivo 
Targeted nerve crush in the lower limb muscles of the right leg was accomplished via acute 10 second 
crushing of the sciatic nerve in the midthigh region using forceps. The procedure was completed under 
isoflurane anaesthesia (3% inhalation) with the use of aseptic surgical techniques. Male mice (C57BL/6; 12 
weeks old) purchased from Charles River Laboratories were given an analgesic (buprenorphine, 0.1 mg/kg) 
immediately and for 48 hours following the surgery and returned to their cage following recovery. Following 
completion of the appropriate time period (3, 7, 14, 21, 28, 45 and 60 days/d; n = 6/ group), mice were 
anesthetized with isoflurane, and the gastrocnemius complex (GSTC) muscles were excised, weighed, 
frozen in liquid nitrogen, and stored at −80°C for later analysis. On completion of tissue removal, mice were 
euthanized by exsanguination. Prior to tissue collection a sciatic nerve test was applied via a single electrical 
pulse to the sciatic nerve through electrodes to observe a twitch response in the hindlimb muscles. Between 
21 and 60 days all animals displayed a twitch, suggesting that neural activity to the hindlimb muscles had 
returned at these time points. A separate untreated cohort of animals (n = 6) were used as relevant controls. 
All animal procedures were approved by the Institutional Animal Care and Use Committee at the University 
of Iowa, Iowa City, USA. 
 
Mechanical loading of bioengineered skeletal muscle in-vitro 
Bioengineered mouse muscle was created using the C2C12 cell line as previously described by our group, 
using a fibrin self-assembling three-dimensional (3-D) model (Turner et al., 2019a). Briefly, C2C12 cells were 
grown on T75’s to approx. 80% confluence whereby 90,000 cells/ml in 2 ml growth media (GM; 4.5 g/l glucose 
DMEM that included 4 mM L-glutamine, 10% hiFBS, 10% hiNBCS, supplemented with an additional 2 mM 
L-glutamine (Girven et al., 2016),100 U/ml penicillin, 100 μg/ml streptomycin, 0.5 mg/ml 6-aminocaproic acid, 
50 μM L-ascorbic acid, 50 μM L-proline) were seeded onto each sylgard coated (Sylgard 184 Elastomer Kit, 
Dow Corning, MI, USA) 35 mm culture dish containing a pre-polymerised (10 mins at room temperature and 
1hr at 37 degrees) fibrin gel made up of 500 μl thrombin-solution (10 U/ml thrombin, 8 μl/ml aprotinin at 10 
mg/ml) and 200 μl fibrinogen (20 mg/ml). GM was changed every 48 h until ~90% confluency was attained. 
Media was then switched to differentiation media (DM; 4.5 g/l glucose DMEM that includes 4 mM L-glutamine, 
2% HS, supplemented with an additional 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ ml streptomycin, 1 
mg/ml 6-aminocaproic acid, 50 μM L-ascorbic acid, 50 μM L-proline) for 48 hrs and then then switched to 7% 
serum (same media constituents as DM with 7% serum, 3.5% hiFBS/ 3.5% hiNBCS) maintenance media 
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(MM) to promote myotube formation for a further 10 days. Bioengineered muscle constructs were then 
transferred to bioreactor chambers (TC-3 Ebers, Spain, see Figure 4bi) for subsequent loading which 
involved 5 exercises × 4 sets × 10 reps (at 0.4 mm/s with 90 s rest between sets, 3.5 mins rest between 
exercises, totalling a stretch regime of 60 mins) at 10% stretch (1.2 mm) at 37C / 5% CO2, recently described 
in full detail (Kasper et al., 2017; Turner et al., 2019a). To identify representative gel morphology (seen in 
Figure 4bi) bioengineered muscle constructs were fixed and dehydrated in ice-cold methanol:acetone:TBS 
(25:25:50) for 15 mins then a further 15 mins in methanol:acetone (50:50) only. Following fixation, gels were 
permeabilised (0.2% Triton X-100) in 1 x TBS for 90 mins and incubated overnight (4°C) in 250 μl Phalloidin-
FITC (Sigma Aldrich, P5282) at a concentration of 50 μg/ml. After overnight incubation, Phalloidin-FITC was 
aspirated and gels were washed 3 x TBS before adding 250 μl of DAPI stain (ThermoFisher, D1306) at a 
concentration of 300 μM for 90 mins to counterstain myonuclei. Myotubes (Phalloidin-FITC, Excitation: 495 
nm, Emission: 513 nm) and myonuclei (DAPI, Excitation: 358 nm, Emission: 461 nm) were visualised under 
an inverted fluorescence microscope (Nikon, Eclipse Ti-S) and imaged (Nikon, NIS Elements) for 
morphological analysis. RNA was isolated 30 minutes post-stretch to assess UBR5 transcript expression 
versus static non-loaded controls.  
 
Intermittent high frequency chronic electrical stimulation induced hypertrophy in-vivo    
In adult male Wistar rats (6 months of age), under anaesthesia with isoflurane and buprenorphine, a sterilised 
miniature implantable stimulator was inserted into the abdominal cavity and sutured to the abdominal wall 
with electrodes placed near to the common peroneal and tibial nerves. The muscles were electrically 
stimulated to ensure that the dorsiflexors worked against the plantar-flexors, and therefore the dorsi-flexors 
were ‘loaded’. The stimulation consisted of an intermittent regime of high frequency (100 Hz) stimulation once 
a day for 4 weeks (5 sets x 10 reps, each rep 2s with 2s rest between reps, and 2.5 minutes rest between 
sets). Daily stimulation was conducted under no anaesthesia and amplitude of nerve stimulation was 
remotely adjusted under careful observation to provide motor-neurone activation without limb withdrawal or 
signs of distress. Following 4 weeks of the above regime there was an average 14% increase in muscle 
weight and an 19% increase in fiber CSA in the TA muscle at the mid-belly as previously described (Schmoll 
et al., 2018). DNA and RNA was isolated from TA muscle from this original study (Schmoll et al., 2018) from 
both the stimulated and contralateral (unstimulated) control limbs (n = 4) at the end of the 4 weeks electrical 
stimulation protocol. Experimental procedures were conducted according to the permissions within a project 
license granted under the British Home Office Animals (Scientific Procedures) Act 1986. Wistar rats were 
sourced from registered breeding colonies at LJMU Life Sciences Support Unit and euthanasia was 
conducted by rising CO2 followed by cervical dislocation. 
 
Synergist ablation/functional overload (FO) in-vivo 
Hypertrophy of the plantaris muscle was induced in male C57BL/6 mice (12 weeks old) by surgical removal 
of synergist muscles (entire soleus and over half of the medial and lateral gastrocnemius without damaging 
the plantaris neural-vascular supply) according to a previously validated method termed synergist ablation or 
functional overload (FO) (McCarthy et al., 2011; Bodine & Baar, 2012; Jackson et al., 2012). The same 
protein lysates at baseline (control), 1, 3, 10 and 14 days (d) following FO previously derived in (Baehr et al., 
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2014), that demonstrated significant increases in muscle weight of 43 and 65% after 7 and 14 d respectively, 
were analysed in new experimentation for UBR5 protein abundance in the present study (n = 3 / group).  
C57BL/6 mice were purchased from Jackson Laboratories. Mice were anaesthetized with inhaled 
isoflurane. Following tissues collection, the mice were euthanized by exsanguination. All animal procedures 
were approved by the Institutional Animal Care and Use Committee at the University of California, Davis, 
USA. 
 
Human muscle biopsies, cell isolation and differentiation in-vitro 
Human muscle cells were isolated from the vastus lateralis biopsies of 3 healthy young adult males (28 ± 11 
yr, 73.00 ± 0.91 kg, 177.2 ± 4.3 cm, means ± SD) who were recreationally active but had never undergone a 
period of supervised chronic aerobic or resistance exercise. Full biopsy procedure and primary cell isolation 
procedures are provided in (Seaborne et al., 2018a; Seaborne et al., 2018b; Turner et al., 2019a; Turner et 
al., 2019b). Ethical approval was granted by the NHS West Midlands Black Country, UK, Research Ethics 
Committee as previously reported (Seaborne et al., 2018b). Briefly, conchotome biopsies were immediately 
transferred to a sterile class II BSC in pre-cooled transfer media (TM; Hams F-10, 2% hi-FBS, 100 U/ml 
penicillin, 100 μg/ml streptomycin and 2.5 µg/ml amphotericin-B) and any connective/adipose tissue removed 
using a sterile scalpel on a petri dish in the same transfer media. Biopsies were then washed in sterile PBS 
(plus 100 U/ml penicillin, 100 µg/ml streptomycin and 2.5 µg/ml amphotericin-B), scissor minced in the 
presence of 0.05% Trypsin/0.02% EDTA and then titrated on a magnetic stirring platform at 37°C, with this 
procedure repeated twice. The supernatant following each of these procedures was then collected and 
pooled with horse serum at 10% of the total supernatant volume to neutralize the trypsin. The supernatants 
from each treatment were then pooled and centrifuged at 340 rcf for 5 minutes to generate a cell pellet. The 
supernatant was plated in a T25 (as a backup source of any cells remaining) and the cell pellet was 
resuspended on a separate T25, both in growth media/GM (GM; Ham’s F10 nutrient mix supplemented with 
10% hi-NCS, 10% hi-FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin B and 5 mM 
L-glutamine). Once confluent cells were split onto larger T75’s to generate enough cells to perform 
differentiation experiments. Human derived muscle cells were then seeded onto gelatin coated 6 well plates, 
at a density of 9x105 cells/ml in 2 ml of GM for 24 hrs prior to removal of GM, 3 x PBS washes and transfer 
to differentiation media (DM; Ham’s F10 nutrient mix supplemented with 2% hiFBS, 100 U/ml penicillin, 100 
µg/ml streptomycin, 2.5 µg/ml amphotericin B and 5 mM L-glutamine) for a period of 7 days. Cells were lysed 
for protein at 0 hrs (30 minutes in DM), 72 hrs and 7 days after transfer to DM. All experiments were carried 
out below passage 10 to prevent senescence.  
 
Human micro-array methods and association analyses 
The human association studies involved 357 Russian international-level athletes (age 24.0  3.6 years; 192 
males and 165 females), 84 physically active men and 173 controls (83 males and 90 females). The athletes 
were stratified into 4 groups according to type, intensity, and duration of exercise. The first group (n = 142) 
included long-distance endurance athletes (3-10 km runners, biathletes, 5-10 km skaters, cross-country 
skiers, marathon runners, 0.8-25 km swimmers, race walkers, and triathletes. The second group (n = 115) 
comprised of sprinters (50-100 m swimmers, 200 m kayakers and canoers, sprint cyclers, 100-400 m runners, 
 9 
500-1000 m skaters and short-trackers). The third group (n = 73) included strength athletes (powerlifters and 
weightlifters). The fourth group comprised explosive power athletes with predominantly anaerobic energy 
production (arm-wrestlers, track and field jumpers, heptathletes / decathletes and throwers). There were 198 
athletes classified as ‘elite’ (prize winners of major international competitions). There were 159 athletes 
classified as ‘sub-elite’ (participants in international competitions). Physically active men (n=84; age 33.1  
7.3 years, height 180.1  6.2 cm, weight 81.0  10.4 kg were involved in the muscle biopsy study. Russian 
controls were 173 unrelated citizens of Russia without any competitive sport experience. The athletes and 
controls were all Caucasians of Eastern European descent. The overall study was approved by the Ethics 
Committee of the Physiological Section of the Russian National Committee for Biological Ethics and Ethics 
Committee of the Federal Research and Clinical Centre of Physical-Chemical Medicine of the Federal 
Medical and Biological Agency of Russia. Written informed consent was obtained from each participant. The 
study complied with the guidelines set out in the Declaration of Helsinki and ethical standards in sport and 
exercise science research.  
 
Molecular genetic analysis in all Russian athletes, physically active men and controls was performed with 
DNA samples obtained from leukocytes (venous blood). Four ml of venous blood were collected in tubes 
containing EDTA (Vacuette EDTA tubes, Greiner Bio-One, Austria). Blood samples were transported to the 
laboratory at 4°C and DNA was extracted on the same day. DNA extraction and purification were performed 
using a commercial kit according to the manufacturer's instructions (Technoclon, Russia) and included 
chemical lysis, selective DNA binding on silica spin columns and ethanol washing. Extracted DNA quality 
was assessed by agarose gel electrophoresis. HumanOmni1-Quad BeadChips (Illumina Inc, USA) were used 
for genotyping of 1,140,419 SNPs in athletes and controls and HumanOmniExpress BeadChips (Illumina Inc, 
USA) were used for genotyping of > 700,000 SNPs in participants of the Muscle Fiber Study (84 physically 
active men). The assay required 200 ng of DNA sample as input with a concentration of at least 50 ng/µl. 
Exact concentrations of DNA in each sample were measured using a Qubit Fluorometer (Invitrogen, USA). 
All further procedures were performed according to the instructions of the Infinium HD Assay.  
 
Evaluation of muscle fiber composition and cross-sectional area 
Samples of the vastus lateralis muscle of Russian athletes were obtained with the Bergström needle biopsy 
procedure under local anaesthesia with 1% lidocaine solution. After this procedure, serial cross-sections 
(sections cut after on another) (7 μm) were obtained from frozen samples using a microtome (Leica 
Microsystems, Wetzlar, Germany). The sections were thaw-mounted on Polysine glass slides, kept for 15 
min at RT and incubated with in PBS (3  5 min). Then one of the serial sections was incubated at RT in 
primary antibody against a slow isoform of the myosin heavy chains and the second serial section against a 
fast isoform of the myosin heavy chains (M8421, 1:5000; M4276; 1:600, respectively; Sigma-Aldrich, USA) 
for 1 h and incubated in PBS (3  5 min). After this, the serial sections were incubated at RT in a secondary 
antibody conjugated with FITC (F0257; 1:100; Sigma-Aldrich) for 1 hr. The sections were then washed in 
PBS (3  5 min), placed in mounting media and covered with a cover slip. The image was captured using a 
fluorescent microscope Eclipse Ti-U (Nikon, Japan). All analyzed images contained > 100 fibers. An example 
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of stained images for slow and fast fibres can be seen in Figure 5A). The ratio of the number of stained fibers 
to the total fiber number was calculated. Fibers stained in serial sections with antibodies against both slow 
and fast isoforms were considered as hybrid fibers. The cross-sectional area (CSA) of fast and slow fibers 
was evaluated using ImageJ software (NIH, USA). 
 
Strength measurement 
Evaluation of strength in elite Russian weightlifters was assessed by their performance in snatch, and clean 
and jerk (best results in official competitions including Olympic Games, Europe and World Championships). 
The total weight lifted (in kg) was multiplied by the Wilks Coefficient (Coeff) to find the standard amount lifted 
normalised across all body weights. Coeff =
500
a+bx+cx2+dx3+ex4+fx5
, where x is the body weight of the weightlifter 
in kilograms. Values for males were: a = -216.0475144; b = 16.2606339; c =-0.002388645; d = -0.00113732; 
e = 7.01863E-06; f = -1.291E-08. Values for females were: a = 594.31747775582, b = -27.23842536447; c 
= 0.82112226871; d = -0.00930733913; e = 4.731582E-05; f = -9.054E-08. 
 
Gene expression by rt-qRT-PCR 
Tissue from TTX atrophy/recovery, high frequency chronic intermittent electrical stimulation, continuous low 
frequency ‘overtraining’ stimulation and bioengineered muscle was homogenised in Tri-Reagent (Invitrogen, 
Loughborough, UK) for 45 seconds at 6,000 rpm x 3 (5 minutes on ice in between intervals) using a Roche 
Magnalyser instrument (Roche, Germany) and homogenization tubes containing ceramic beads (MagNA 
Lyser Green Beads, Roche, Germany). Human cells from differentiation experiments in monolayer were also 
lysed in Tri-Reagent for 5 minutes before being removed from the wells using a sterile cell scraper. RNA was 
then isolated from all these models using the manufacturer’s instructions for Tri-Reagent. In a one-step 
reaction (reverse transcription and PCR) qRT-PCR was performed using a QuantiFastTM SYBR
® 
Green RT-
PCR one-step kit on a Rotorgene 3000Q, with a reaction setup as follows; 4.75 μl experimental sample (7.36 
ng/μl totalling 35 ng per reaction), 0.075 μl of both forward and reverse primer of the gene of interest (100 
μM stock suspension), 0.1 μl of QuantiFast RT Mix (Qiagen, Manchester, UK) and 5 μl of QuantiFast SYBR 
Green RT-PCR Master Mix (Qiagen, Manchester, UK). Reverse transcription initiated with a hold at 50oC for 
10 minutes (cDNA synthesis) and a 5-minute hold at 95oC (transcriptase inactivation and initial denaturation), 
before 40-45 PCR cycles of; 95oC for 10 sec (denaturation) followed by 60oC for 30 secs (annealing and 
extension). Primer sequences for genes of interest and reference genes across mouse, rat and human 
samples are included in Table 1. All genes of interest and reference gene primers across species 
demonstrated no unintended targets via BLAST search and yielded a single peak after melt curve analysis 
conducted after the PCR step above. All relative gene expression was quantified using the comparative Ct 
(∆∆Ct) method (Schmittgen & Livak, 2008). For rat experiments that included gene expression (e.g. TTX 
atrophy-recovery, continuous low frequency electrical stimulation ‘overtraining’-induced atrophy and high 
frequency intermittent electrical stimulation induced hypertrophy), the contralateral control limb was used in 
∆∆Ct equation as the calibrator condition. For bioengineered mouse muscle the pooled value from the static 
unloaded controls were used as the calibrator condition due to demonstrating low variation in Ct value (mean 
± SD, 18.5 ± 0.8, 4.3% variation). Finally, for human cell differentiation the 0 hrs control sample within each 
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subject was used as the calibrator. The average Ct value for the human cell differentiation experiments 
(RPL13a), rat (Polr2a) and mouse (Pol2rb) reference genes were also consistent across all samples and 
experimental conditions (human cell differentiation (mean Ct ± SD): 14.8 ± 0.5, rat TTX 21.8 ± 1.1, rat 20Hz 
continuous low frequency stimulation ‘overtraining’ 21.8 ± 1, rat intermittent high frequency 100Hz stimulation  
23.2 ± 0.7, mouse bioengineered muscle 18.3 ± 0.7) with small variations of 3.5, 4.9, 4.7, 2.8, 3.9% 
respectively. The average PCR efficiencies of UBR5 (human cell differentiation 91.8%, rat TTX 91.7%, rat 
20Hz continuous low frequency stimulation ‘overtraining’ 92.5%, rat intermittent high frequency 100Hz 
stimulation 90.4%, mouse bioengineered muscle 93.8%) were comparable with the human reference gene 
RPL13a (97.2%), rat reference Pol2ra gene (rat TTX 93.9%, rat 20Hz continuous low frequency stimulation 
‘overtraining’ 93.5%, rat intermittent high frequency 100Hz stimulation 90.9%) and mouse Pol2rb gene 
(mouse bioengineered muscle 91.6%).  
 
Finally, for nerve crush injury model experiments, frozen muscle powder was homogenised using RNAzol 
RT reagent (Sigma-Aldrich, St Louis, USA) according to the manufacturer's instructions. cDNA was 
synthesized using a reverse transcription kit (iScriptTm cDNA synthesis kit, Bio-rad, USA) from 1 μg of total 
RNA. 10 μl PCR reactions were setup as follows: 2 μl of cDNA, 0.5 μl (10 μM stock) forward and reverse 
primer, 5 μl of Power SYBRTM Green master mix (Thermofisher Scientific, USA)) and 2 μl of RNA/DNA free 
water. Gene expression analysis was then performed by quantitative PCR (qPCR) on a Quantstudio 6 Flex 
Real-time PCR System (Applied Biosystems) using the UBR5 mouse primers in Table 1 (also used in the 
other mouse bioengineered muscle analysis). PCR cycling was as follows hold at 50oC for 5 minutes, 10-
minute hold at 95oC, before 40 PCR cycles of; 95oC for 15 sec followed by 60oC for 1 minute (combined 
annealing and extension). Primer testing in these nerve crush samples yielded 89.04% efficiency for UBR5. 
As above, melt curve analysis at the end of the PCR cycling protocol yielded a single peak. For these 
experiments due to reference gene instability, after first assessing total RNA/mg tissue and then taking the 
∆Ct expression value, the mRNA was described relative to tissue weight, and then described as fold change 
relative to control muscles as previously described (Heinemeier et al., 2009) an analysis used extensively by 
the group previously (Baehr et al., 2016; Baehr et al., 2017; Hughes et al., 2018). 
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DNA methylation by pyrosequencing 
DNA samples from cells and tissue were isolated using Qiagen’s DNA easy blood and tissue kit (Manchester, 
UK) and bisulfite converted using Zymo Research EZMethylation Kit (Zymo Research, Irvine, CA, USA) as 
per manufacturer’s instructions. Prior to DNA isolation tissue samples were homogenized for 45 seconds at 
6,000 rpm x 3 (5 minutes on ice in between intervals) in the lysis buffer (buffer ATL and protinase K) provided 
in the above DNA isolation kits using a Roche Magnalyser instrument and homogenization tubes containing 
ceramic beads (Roche, UK). UBR5 PCR primers and pyrosequencing primers were purchased from 
EpigenDX (Hopkinton, MA, USA), rat assay no: ADS5785 and mouse assay no: ADS5784, summarized in 
Table 2. PCR reactions were setup as follows; 3 μl of 10X PCR buffer (containing 15 mM MgCl2), plus an 
additional 1.8 μl of 25 mM MgCl2, 0.6 μl of 10 mM dNTPs, 0.15 μl HotStar Taq Polymerase (5 U/µl), 1 µl of 
bisulfite treated DNA and 0.6 μl of forward and reverse primer (10 µM). One primer was biotin-labelled and 
HPLC purified in order to facilitate purification of the final PCR product using streptavidin sepharose beads 
(see below). Following an initial denaturation incubation at 95°C for 15-min, for the Rat UBR5 assay; 45 
cycles of denaturation at 95°C for 30 s; 51°C for 30 s (annealing), 68°C for 30 s (extension) were performed, 
with all PCR cycles followed by a final 5 minutes at 68°C. The mouse UBR5 assay had the same cycling 
parameters except for the annealing step that was conducted at 51°C for 30 s. PCR products were then 
bound to 2 µl Streptavidin Sepharose HP (GE Healthcare Life Sciences) in 40 µl Binding Buffer (Pyromark 
binding buffer, Qiagen, Manchester UK) and 25 µl Milli-Q-water. After which the immobilized PCR products 
were purified, washed, denatured with a 0.2 μM NaOH solution and rewashed using the Pyrosequencing 
Vacuum Prep Tool (Pyrosequencing, Qiagen, Manchester, UK), as per the manufacturer’s instructions. The 
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denatured and washed PCR products were then placed in annealing buffer (Pyromark annealing & wash 
buffers, Qiagen, Manchester UK) with 0.5 μM sequencing primer at 75°C for two minutes on a heating block 
and the block then turned off for 10 minutes with the samples left in the block and then a further 10-15 minutes 
to cool at room temperature. Sequencing of the single stranded products yielded after PCR was conducted 
on a PSQ96 HS System (Qiagen, Manchester, UK) using Pyromark Gold Q24/Q96 reagents (Qiagen, 
Manchester, UK) following the manufacturer’s instructions. Methylation status of the individual CpG sites was 
identified as an artificial C/T SNP using QCpG software (Pyrosequencing, Qiagen, UK). Then % methylation 
of each CpG site was then calculated as a proportion of the methylated alleles divided by the sum of all 
methylated and unmethylated alleles, with the average methylation also then calculated across all CpG sites 
analysed within each gene. Non-CpG cytosines were included as internal controls for detection of incomplete 
bisulfite conversion. Furthermore, unmethylated and methylated DNA strands were included as controls after 
each PCR and bias testing was conducted by unmethylated control DNA mixed with in vitro methylated DNA 
at different ratios (0%, 5%, 10%, 25%, 50%, 75% and 100%). All supporting information for gene assays, 
including assay genomic sequence, bisulfite converted sequence and pyrosequencing dispensation order, 
CpG island locations, position from transcriptional start site and CpG ID numbers are given in Table 2.  
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SDS page and western blotting 
For UBR5 protein analysis from the hindlimb unloading, nerve crush and functional overload models, medial 
gastrocnemius (MG), gastrocnemius complex (GSTC) and plantaris muscle respectively were homogenized 
in sucrose lysis buffer (50 mM Tris pH 7.5, 250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1% Triton X 100, 50 
mM NaF). The supernatant was collected following centrifugation at 8,000 g for 10 minutes and protein 
concentrations were determined using the PierceTM 660 nm protein assay reagent (Thermo Scientific, 
Waltham, USA). Twelve micrograms of protein were subjected to SDS-PAGE on 4-20% Criterion TGX stain-
free gels and transferred to polyvinylidene diflouride membranes. Membranes were blocked in 3% non-fat 
milk in Tris-buffered saline (TBS) with 0.1% Tween-20 (TBST) added for one hour and then probed with 
primary antibody overnight at 4°C (monoclonal UBR5 antibody, D6087; Cell Signalling Technology 1:500). 
Membranes were washed and incubated with HRP-conjugated secondary antibodies at 1:10,000 for one 
hour at room temperature. Immobilon Western Chemiluminescent HRP substrate was then applied to the 
membranes prior to image acquisition. Image acquisition and band quantification were performed using the 
Azure C400 System and Image Lab 6.0.1 software, respectively. Total protein loading of the membranes 
captured from images using stain-free gel technology (described above) was used as the normalization 
control for all blots for data from the hindlimb unloading, nerve crush and functional overload models. The 
same control lysates were run on two western blots to allow for quantification of UBR5 protein across multiple 
time points with the nerve crush injury analysis. 
 
For human cell differentiation experiments, cell monolayers were lysed with trypsin and centrifuged at 
18,000g to pellet the cells. The supernatant was discarded, and the remaining pellet was immediately frozen 
in liquid nitrogen. For the isolation of total protein, cell pellets were re-suspended in ice cold 
radioimmunoprecipitation assay (RIPA) buffer (Thermo Scientific) containing protease and phosphatase 
inhibitor cocktail (cOmplete Mini Protease Inhibitor Cocktail; Roche). The cell solution was kept on ice for ten 
minutes, following which samples were sonicated and vortexed before total protein content was determined 
by a bicinconinic acid assay (BCA) (Pierce, Thermo Fisher). Samples were then diluted to a final 
concentration of 1 µg/µl in 4x Laemmli buffer (Bio-Rad) and ultra-pure water and boiled for 10 minutes to 
denature proteins. For the determination of UBR5 abundance, equal amounts of protein (20 ug) were 
separated using SDS-PAGE on 6% gels at a constant voltage of 100 V per gel. Protein was then transferred 
onto a nitrocellulose membrane by wet transfer at 30 V overnight at 4oC in Towbin buffer. Protein transfer 
was assessed by ponceau red staining (Sigma-Aldrich). Membranes were blocked with 5% bovine serum 
albumin (BSA) in TBST and then incubated overnight at 4oC with a monoclonal UBR5 antibody (D6087; Cell 
Signalling Technology) and GAPDH (14C10; Cell Signalling Technologies) at a working concentration of 
1:500 and 1:1000 in 5% BSA-TBST, respectively. Following 3x10 min TBST washes, membranes were 
washed in TBST 3x10 minutes prior to incubation in appropriate horse radish peroxidase-conjugated 
secondary antibody at room temperature for one hour. Chemiluminescent substrate was added to 
membranes and visualised in a Chemi-doc MP imaging system (Bio-Rad). Integrated density was determined 
for each band and all bands were normalized to GAPDH. 
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Muscle specific knock-down of UBR5 for antibody validation 
To confirm that the UBR5 antibody above (monoclonal UBR5 antibody, D6087; Cell Signalling 
Technology) used in the western blots was specific for UBR5. We use an RNAi system which was designed 
and purchase via Invitrogen (Massachusetts, USA). Specifically, the negative control RNAi plasmid was 
described previously (Ebert et al., 2012) and encodes emerald green fluorescent protein (EmGFP) and a 
non-targeting pre-miRNA under bicistronic control of the CMV promoter in the pcDNA6.2GW/EmGFP-miR 
plasmid (Invitrogen). The UBR5 RNAi plasmid encodes EmGFP and an artificial pre-miRNA targeting mouse 
UBR5 under bicistronic control of the CMV promoter; it was generated by ligating the Mmi571982 
oligonucleotide duplex (Invitrogen) into the pcDNA6.2GW/EmGFP-miR plasmid. The designed plasmids 
were incubated at 37°C overnight with TopOne Shot cells (Thermofisher Scientific cat no. C404010) on LB 
Agar Bacterial resistant plates (50 µg/ml Spectinomycin Sigma Aldrich cat no. S4014) in SOC medium 
(Invitrogen cat no. 15544-034), with isolated colonies then incubated/grown overnight in an orbital shaker at 
37°C in falcon tubes. Bacteria where then pelleted at 6800 g for 1 min. Plasmid DNA from the bacteria was 
then prepared using a maxi prep kit (Nucleobond Xtra Maxi EF, Cat no. 740424.50 Machery-Nagel, USA) as 
per manufacturer’s instructions. The electroporation of DNA plasmids was performed as previously described 
(Ebert et al., 2010; Hughes et al., 2018). Briefly, after a 2 hr pre-treatment with 0.4 units/µl of hyaluronidase, 
20 µg of mIR RNAi or negative control plasmid was injected into the TA muscle in C57/BL6 male mice (12-
16 week-old, n = 5; purchased from Charles River Laboratories) and the hind limbs were placed between 
two-paddle electrodes and subjected to 10 pulses (20 msec) of 175 V/cm using an ECM-830 electroporator 
(BTX Harvard Apparatus). It has been previously demonstrated that the use of a pre-treatment with 
hydaluronidase allows for enhanced levels of transfected muscle without increased levels of muscle damage 
during the electroporation process (McMahon et al., 2001). The TA muscle was harvested for western blot 
analysis after 7 days post electroporation. On completion of tissue removal, mice were euthanized by 
exsanguination. All animal procedures were approved by the Institutional Animal Care and Use Committee 
at the University of Iowa, Iowa City, USA.  We subsequently confirmed that UBR5 protein abundance was 
significantly reduced following injection of the UBR5 RNAi plasmid into basal skeletal muscle (Figure 1B). 
 
Figure 1: A: Reductions in muscle weight after 7 days of continuous low frequency (20Hz) electrical stimulation. TA weight was 
expressed relative to whole animal body mass to normalize for interindividual differences in animal size (n = 6). Then expressed as 
percentage change from the untreated contralateral control limb for each animal. B: UBR5 RNAi and negative control (neg con) 
plasmid injected into the TA muscle of C57/BL6 male mice (n = 5) after 7 days post electroporation. Western blots using UBR5 
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antibody (monoclonal, D6087; Cell Signalling Technology) demonstrate a significant reduction (p value depicted on figure) in UBR5 
protein, validating the antibody for use in skeletal muscle. 
Statistics 
TTX atrophy/recovery, FO induced hypertrophy and nerve crush models used a two-way ANOVA with an 
appropriate post-hoc correction (Fishers LSD). Human cell differentiation experiments were analysed using 
a one-way ANOVA with Fisher LSD post-hoc test. Those with an experimental group versus a relevant control 
were analysed using t-tests (chronic low frequency electrical stimulation induced atrophy, intermittent high 
frequency- electrical stimulation induced hypertrophy, loading of bioengineered muscle, UBR5 antibody 
validation). Biological repeat numbers (n) are specific in the methods sections or associated figure legends. 
Human microarray and association study data were analysed using PLINK v1.90, R (version 3.4.3), and 
GraphPad InStat (GraphPad Software, Inc., USA) software. Differences in phenotype between different 
genotype groups were analysed using Wald test (for three genotypes). Allele frequencies between groups of 
athletes and controls were compared by χ2 testing. P values  0.05 were considered statistically significant.  
 
Results  
UBR5 following skeletal muscle atrophy and recovery 
Utilising a novel in-vivo model of disuse, whereby the common peroneal nerve of Wistar rats was exposed to 
tetrodotoxin (TTX) for 3, 7 and 14 days, we were able to successfully induce progressive skeletal muscle 
atrophy, as we previously described (Fisher et al., 2017). Here, we reanalyzed RNA/DNA from these samples 
and identified that UBR5 gene expression significantly increased early in the time-course of atrophy (3 days, 
p = 0.04), coincident with significant hypomethylation of the UBR5 promoter (p = 0.004, Figure 2A). UBR5 
gene expression remained elevated at 7 days following TTX induced atrophy (p = 0.04) but reduced later at 
14 days, by which time the most extensive muscle mass loss occurred (51% loss in muscle weight), 
suggesting that increased UBR5 may be associated with early remodelling as a result of atrophy, but not 
later in the timecourse where the most extensive atrophy occurred. To further support and investigate these 
findings, we examined a secondary muscle mass loss stimulus in-vivo. We exposed Wistar rats to continuous 
low frequency electrical stimulation (20 Hz) for 7 days to mimic a model of over-use induced atrophy, which 
we successfully accomplished (12.64% reduction in muscle weight; Figure 1A). Interestingly, we identified 
that UBR5 did not significantly increase compared to control (p = N.S), whereas MuRF1 and MAFbx were 
significantly increased (Figure 2B; MuRF1 p = 0.01, MAFbx P = 0.03). 
 
To examine the temporal pattern of UBR5 during recovery of skeletal muscle, we utilised our 14 d TTX 
atrophy model with an extended 7 day TTX cessation period to allow recovery from atrophy. This model 
successfully recovered skeletal muscle mass and CSA by 52 and 63% respectively (Fisher et al., 2017). In 
this recovery model, we identified significant hypomethylation of UBR5 promoter (p = 0.04, Figure 2A) with 
an average increase in gene expression of UBR5 that did not quite reach significance (p = 0.1; Figure 2A & 
C). Importantly, MuRF1 and MAFbx were also significantly increased at the gene expression level at 3 and 
7 days post TTX-induced atrophy (all p  0.01), as previously described in (Fisher et al., 2017), yet these E3 
ligases were upregulated to a greater extent (larger fold change) over the time course of atrophy than UBR5 
(Figure 2C), and importantly were downregulated at the gene expression level during recovery. During 
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recovery of muscle, UBR5 showed a trend for upregulation (1.91 fold) (albeit non-significantly p = 0.1) versus 
MuRF1 and MAFbx that were supressed below baseline levels (downregulated) that resulted in a reduction 
vs. the 14 d TTX atrophy timepoint (p = 0.08, Figure 2C). This pattern of UBR5 upregulation and MuRF1 and 
MAFbx suppression during muscle growth was also observed after chronic intermittent stimulation induced 
hypertrophy in rats (p = 0.02, described below in the results and depicted in Figure 4ci). Overall, these data 
suggest that UBR5 hypomethylation (significant) and an increase in gene expression (non-significant/p = 0.1) 
were associated with recovery from atrophy and muscle growth (Figure 2A & C).  
 
 
Figure 2. A: UBR5 DNA methylation and gene expression during Tetrodotoxin (TTX) atrophy and recovery in rat tibialis anterior (TA) 
(n = 6 for 3/7/14 days (d); n = 4 for recovery). Significant (*) increases in gene expression of UBR5 at 3 and 7 d. Significant (*) 
hypomethylation of the UBR5 promoter at 3 and 14 d of TTX and after 7 days recovery. B: No change in UBR5 gene expression 
compared with significant increases in MuRF1 (*) and MAFbx (**) after 13% muscle mass atrophy as a result of ‘overtraining’ induced 
by continuous low frequency (20Hz) electrical stimulation (CLFS) (n = 3). C: UBR5 gene expression in comparison with MuRF1 and 
MAFbx taken from previously published data in the same conditions/samples (Fisher et al., 2017) during TTX atrophy and recovery 
from atrophy (n = 6 for 3/ 7 / 14 d, n = 4 for recovery). All genes significantly increased early during atrophy at 3 (*) & 7 () days, but 
with larger absolute fold changes in MuRF1/MAFbx vs. UBR5. During recovery MuRF1 and MAFbx were downregulated (MuRF1, p 
= 0.08 vs. 14 D) whereas UBR5 was upregulated (p = 0.1 vs. control). D & E: Protein abundance of UBR5 during hindlimb unloading 
(HU) induced atrophy and reloading/recovery (/REL) in the medial gastrocnemius muscle of adult (D) and aged (E) rats (n = 6/group). 
UBR5 was increased early after 3 d atrophy without significance. UBR5 then returned to baseline after 14 days of HU. Then in both 
adult (D) and aged (E) muscle UBR5 rapidly increased during recovery/REL resulting in significance (*) at 14 days in adult rats (p = 
0.057), and both 7 and 14 days in aged rats (*). All graphs are means  SEM. Significance at the level of p  0.05 unless otherwise 
stated.  
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It is worth noting that in the TTX model, only 7 days of recovery was sufficient to reverse a loss of 
approximately half the weight of the TA seen after 14d of TTX.  Therefore, this could be an explanation for 
observing significant hypomethylation (that precedes gene expression) yet a non-significant average 
increase in UBR5 gene expression itself. To further investigate changes in UBR5 gene and protein 
expression, we used another well characterised model of disuse atrophy and recovery, hind-limb unloading 
(HU) and recovery/reloading. In this model we analysed the medial gastrocnemius (MG) of adult rats that has 
previously been characterised to demonstrate a full recovery of mass after 14 days following resumed 
habitual physical activity (reloading) post HU induced-atrophy (Baehr et al., 2016). Furthermore, as aging 
results in reduced muscle mass and an impaired recovery from atrophy (Baehr et al., 2016) versus adult rats, 
we also examined changes in UBR5 in response to HU atrophy and reloading (recovery) in aged rats. Indeed, 
following 14 days of hind-limb suspension in adult and aged rats, UBR5 protein increased early (3 days, 
albeit non-significantly) during atrophy but returned to baseline by 7-14 days in both adult and aged skeletal 
muscle (Figure 2D & E adult and aged respectively). Importantly, during recovery of the MG following hindlimb 
unloading, the largest increase in UBR5 protein was observed, demonstrating significant increases at 7 and 
14 days post loading in young adult (p = 0.057 at 14 d) and aged rats (both p = 0.02 at 7 and 14 d, Figure 
2D & E). Overall, these data suggest that UBR5 protein increased in abundance and was associated with 
early remodelling during atrophy, similarly to the mRNA responses observed in the TTX atrophy model, and 
importantly were associated with muscle growth and remodelling during the reloading/recovery period in both 
adult and aged rats. 
 
UBR5 after nerve crush injury  
Because increased UBR5 was associated with recovery from atrophy we further sought to characterise its 
changes in a relevant muscle injury model of atrophy/recovery using a nerve crush approach. The sciatic 
nerve in the right lower limb of C57BL/6 mice was crushed resulting in denervation and subsequent 
reinnervation of the lower limb muscles by their original motoneurons. This model resulted in a significant 
reduction in weight of the gastrocnemius complex (GSTC) at 7, 14, 21 and 28 d (all p  0.05), the largest 
reduction (38% in muscle weight) occurring prior to reinnervation at 14 days post nerve crush injury (Figure 
3A). The muscle fully recovered after 48 - 60 days (31 - 46 days after maximal atrophy) demonstrated by no 
significant changes vs. baseline controls (at 45 and 60 days, both p  0.05). As with TTX and HU atrophy, 
UBR5 gene expression and protein abundance significantly increased early 3 days following nerve crush 
injury (Figure 3B gene expression, Figure 3D protein abundance, all P = 0.001). Furthermore, UBR5 gene 
expression dropped below baseline after 7 days (Figure 3B), whereas MuRF1 and MAFbx remained elevated 
(Figure 3C & D, albeit not significantly vs. baseline controls, they were significantly elevated vs. UBR5 at 7 
days, both p = 0.01 for both MuRF1/MAFbx vs. UBR5). However, unlike recovery from TTX atrophy or HU 
during the recovery period, after 14 to 60 days of nerve crush injury, gene expression did not increase (Figure 
3B) but significantly decreased in a similar fashion to MuRF1 and MAFbx (Figure 3C & D, all P = 0.001). 
However, importantly (and in an inverse relationship to UBR5 gene expression), protein abundance of UBR5 
significantly increased over the time-course of recovery from nerve crush (Figure 3E) culminating in 
significant increases at 28 and 45 d (both P = 0.001), similar to the increase demonstrated above following 
recovery from HU. 
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Figure 3. A: Muscle weight (mg) of the gastrocnemius complex muscles (GSTC) in mice after nerve crush injury (NCI) over a period 
of atrophy (3 -14 days/d) and recovery (14 d - 60 d) of muscle mass. The mice demonstrated a significant reduction in muscle weight 
of the GSTC at 7, 14, 21 and 28 d (all p  0.05 *) culminating in the largest average reduction of 38% in muscle weight at 14 days 
post nerve crush injury after which point the muscle fully recovered between 45 - 60 days (31 - 46 days after maximal atrophy) 
demonstrated by no significant changes vs. baseline controls at 45 and 60 days (both p  0.05). B, C, D: UBR5 (B), MuRF1 (C) and 
MAFbx (D) significantly ( p  0.001) increased at the gene expression level after 3 d post nerve crush injury and gene expression 
significantly (# p  0.001) decreased at 21, 28, 45- and 60-d post nerve crush injury. UBR5 returned towards baseline at 7 days 
whereas MuRF1 and MAFbx remained elevated at this timepoint post nerve crush injury (both p = 0.01  vs. UBR5 at 7 days, depicted 
on figure C & D). E: UBR5 protein abundance significantly increased early at 3 days post nerve crush injury, then returned to towards 
baseline after 7 and 14 d of atrophy and early during recovery at 21 d, before significantly increasing at 28 and 45 d during recovery 
( p  0.001). All graphs are means  SEM. N = 5-6/group. 
 
UBR5 following skeletal muscle anabolism and hypertrophy 
Our recently published data in humans suggests that UBR5 hypomethylation (via 850K DNA methylation 
arrays) and increased gene expression are associated with hypertrophy in humans following training and 
retraining (re-depicted in Figure 4A), with increased UBR5 gene expression positively correlating with 
increases in lean mass in humans (Seaborne et al., 2018b). In the present study, we demonstrate that 
following an acute anabolic mechanical loading regime in mouse bioengineered muscle, there was also a 
significant increase (1.58 fold, p = 0.02) in UBR5 gene expression, as well as MAFBx (1.4 fold, P = 0.03) with 
a trend for increased expression of MuRF1 (1.77 fold, p = N.S) (all Figure 4Bi & Bii). Interestingly, this 
increase in UBR5 was similar to the fold change increase (1.71 fold) we reported previously, in humans after 
acute resistance exercise (Seaborne et al., 2018b) (Figure 4Bi). In this previous paper (Seaborne et al., 
2018b), we identified that CpG methylation change of UBR5 did not change following the acute exercise 
stimulus (only after chronic training). We therefore examined promotor methylation of UBR5 in our 
mechanically loaded bioengineered mouse model to see if these findings translated across different models 
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and species. In accordance with this, we identified that only 1 of the 6 CpG sites investigated in the UBR5 
promoter were hypomethylated and the rest were hypermethylated following the acute anabolic loading 
stimulus, all non-significantly (data available on request). Further, in our original article, we showed an 
increase in gene expression following repeated/chronic resistance exercise (Seaborne et al., 2018b), 
redrawn in Figure 4A). In an attempt to further support these findings, we reanalysed samples from an in-
vivo rat model of chronic intermittent electrical stimulation induced hypertrophy, alongside a 14% increase in 
muscle weight of the TA (Schmoll et al., 2018). Here we confirmed a similar trend as after human hypertrophy 
demonstrated previously ((Seaborne et al., 2018b), redrawn in Figure 4A), with a significant increase in gene 
expression (Figure p = 0.02), and an average global reduction in methylation of the UBR5 promoter that did 
not reach significance (Figure 4Ci). Similarly, to our analysis following atrophy and recovery, we examined 
whether gene expression changes in UBR5 were similar or different to the other well-known E3 ubiquitin 
ligases, MuRF1 and MAFbx. Interestingly, while we observed a significant increase in UBR5 gene expression 
in the intermittent electrically stimulated hypertrophy model (Figure 4Ci), MuRF1 and MAFbx were 
unchanged in the same model of hypertrophy (Figure 4Cii). Therefore, all the E3 ligases were increased after 
acute mechanical loading but only UBR5 was increased, without an increase in MuRF1/MAFbx, at the gene 
expression level after chronic stimulation induced hypertrophy. 
 
We next sought to determine whether the DNA methylation and gene transcript changes observed was 
related to changes in UBR5 protein abundance using an established model (synergist ablation or functional 
overload/FO) of load induced hypertrophy of the plantaris muscle in mice. We determined, that after a 
significant reduction of UBR5 protein 1 d after FO (p = 0.02), UBR5 was increased rapidly and significantly 
at the protein level at 3, 7 and 14 days over the time-course of hypertrophy (Figure 4D; all p= 0.001) with 
previously determined corresponding significant increases in muscle weight (43 and 65% at 7 and 14 days 
respectively, (Baehr et al., 2014)).  
 
Finally, given the differentiation of satellite cells are important for muscle regeneration, and because previous 
data has described a role for UBR5 in the differentiation of smooth muscle (Hu et al., 2010)), we decided to 
analyse the temporal gene expression and protein pattern of UBR5 using primary human derived cells over 
a 7-day time-course of differentiation. Herein we demonstrated that cells increasing in morphological 
differentiation across the time course of 0, 72 hrs and 7 d (Figure 4Ei), with gene expression increases in 
MyoD, Myogenin and MYHC2, significant increases in MYHC1 (P = 0.04) and reductions in Myf5 (p = 0.06)  
(Figure 4E ii), did not demonstrate significant increase in UBR5 at the gene expression level (data Available 
on request). However, UBR5 protein increased significantly at 72 hrs (p = 0.01) and 7 days (p = 0.02) across 
the time course of differentiation versus 0 hrs (Figure 4E iii). These data suggest that UBR5 gene expression 
increased after both acute loading of bioengineered muscle in-vitro and chronic intermittent electrical 
stimulation induced hypertrophy in-vivo yet was without changes in mRNA expression during human muscle 
cell differentiation. Furthermore, UBR5 increases in protein abundance after hypertrophy in-vivo and across 
the time-course of human muscle cell differentiation. 
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Figure 4. A: UBR5 gene expression and DNA methylation redrawn using original data (from (Seaborne et al., 2018b) after an initial 
period of resistance exercise induced hypertrophy (loading), followed by exercise cessation (unloading) where muscle mass returned 
to baseline levels, and a later period of resistance exercise induced hypertrophy (reloading). Bi: Top image is a representative 
macroscopic image of c2c12 bioengineered skeletal muscle used as a model to assess UBR5’s response to acute loading. Middle 
image is a representative microscopic image (middle) of C2C12 bioengineered skeletal muscle used as a model to assess UBR5’s 
response to acute loading. Middle image is a representative microscopic image (Nikon, Eclipse Ti-S, 10  magnification, scale bar = 
50 μm) of C2C12 bioengineered muscle stained with Phalloidin (actin- green) and DAPI (nuclei, blue) demonstrating highly aligned 
myotubes in the direction of uniaxial tension. Bottom image is the bioengineered muscle constructs loaded within the bioreactor 
chamber(s) as described in (Turner et al., 2019a). Bii: Significant increase in UBR5 gene expression at 30 minutes post-acute loading 
in bioengineered muscle in-vitro (n = 6 loaded / n = 6 unloaded controls), showing similar fold change increase as human tissue after 
30 minutes of acute resistance exercise (RE) in-vivo in our previous studies (Seaborne et al., 2018b). Ci & Cii: UBR5 gene expression 
significantly increased after a 14% increase in muscle mass as a result of 4 weeks of intermittent high frequency electrical stimulation 
in rats (n = 4), where UBR5 also demonstrated average reductions in DNA methylation albeit non-significantly (Ci). The increase in 
UBR5 gene expression in this model of hypertrophy occurred without increases in MuRF1 and MAFbx (Cii). D: UBR5 protein 
abundance significantly reduced in the plantaris muscle in mice after synergist ablation/functional overload (FO) at 1 day (p = 0.02), 
yet rapidly and significantly increased at 3, 7, and 14 days post FO (all p = 0.001) (n = 3/group). Ei Representative images of 
morphological differentiation of human muscle derived cells in monolayer cultures (n = 3) (scale bar 200 μm), that demonstrated 
increasing differentiation and myotube formation across the time-course. Eii: Myogenic regulatory factors (Myf5, MyoD, Myogenin) 
and MYHC (I & II) gene expression during human muscle cell differentiation identified an average increase in MyoD, Myogenin and 
MYHC I & II and reductions in Myf5 as cells differentiated into myotubes at 72 hrs and 7 days. UBR5 gene expression did not increase 
during differentiation. Eiii: UBR5 however demonstrated significant increases in protein levels at 72 hrs and 7 days of differentiation. 
All graphs are means  SEM. Significance at the level of p  0.05 unless otherwise stated in the figure.  
 
Genetic Association Studies identified that genetic variants of the UBR5 gene were associated with muscle 
fiber size in physically active men and strength / power athlete status 
Given the increase in gene expression and protein abundance of UBR5 in the above rodent models of 
hypertrophy, as well as our previous studies in humans demonstrating a strong correlation for UBR5 gene 
expression with lean leg mass, we tested the hypothesis that genetic variations of the UBR5 gene might be 
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associated with muscle hypertrophy and strength/power related phenotypes. Firstly, we identified genetic 
variations in the UBR5 gene that were associated with altered UBR5 gene expression in humans using GTEx 
(Battle et al., 2017). Using this approach, we identified 13 (rs10110916, rs34695816, rs4302812, rs4621773, 
rs4734621, rs4734624, rs61504846, rs74195880, rs7814681, rs7844623, rs7845636, rs9693239, 
rs9694458) single nucleotide polymorphism (SNPs) that were located in close proximity (i.e., in high linkage 
disequilibrium) near UBR5 gene and were significantly (P≤10-5-10-6) associated with UBR5 gene expression 
in human skeletal muscle. Of those, rs4734621 was available for genotyping in the athletic cohorts and 
controls using micro-array analysis. According to the GTEx, the A allele of the rs4734621 SNP is associated 
(P = 0.000013) with increased expression of the UBR5 gene. It was therefore hypothesized that this allele 
might be favourable for strength and power-related sports. Indeed, our analysis demonstrated that the 
rs4734621 AA genotype was associated with high competition results in elite weightlifters (P = 0.016) and 
the A allele was over-represented in elite strength athletes compared to controls (OR = 1.94, P = 0.04). The 
rs4734621 A allele was also over-represented in elite power (strength + explosive power) athletes compared 
to elite endurance athletes (OR = 2.2, P = 0.04). Next, given that the rs4734621 SNP was unavailable to be 
genotyped in the muscle fibre cohort given the different micro-array platformed used, we identified 
rs10505025 polymorphism in the UBR5 gene was strongly linked (`D=1) with all 13 SNPs (described above) 
near the UBR5 gene, including rs473462. We found that the carriers of the rs10505025 AA genotype had 
significantly (P = 0.024) higher mean (SD) CSA of fast-twitch muscle fibres than carriers of the G allele: AA: 
5796  1526 μm2; GA: 5260  1350 μm2; GG: 4011  983 μm2 (Figure 5B). Furthermore, the rs10505025 A 
allele was significantly over-represented in strength athletes (OR = 2.13, P = 0.05) and sprinters (OR = 2.93, 
P = 0.03) compared to endurance athletes. These genetic data support our primary findings that the UBR5 
gene is associated with skeletal muscle hypertrophy and adaptation to strength/power/resistance training. 
Further, that variations affecting UBR5 gene expression are associated with cross-sectional area of fast-
twitch muscle fibres while favouring strength / power versus endurance status in athletes. 
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Figure 5: A: Example of a slow and fast serial section used for fiber size quantification from human participants. B: Box plot 
demonstrating that there was an increased frequency of large fast fibers within the human population that possessed the AA allele 
of the UBR5 rs10505025 polymorphism. 
 
Discussion 
 
UBR5 in atrophy and recovery from atrophy 
UBR5 is a HECT domain E3 ligase previously uncharacterised during and after skeletal muscle atrophy and 
recovery from atrophy. We demonstrate here that during atrophy evoked by tetrodotoxin (TTX) nerve 
silencing in rats, the UBR5 promoter was significantly hypomethylated and increased at the gene expression 
level early (3 days) in the time course of atrophy yet had returned to normal expression levels during later 
atrophy (14 days) where muscle mass loss was greatest. We have also previously demonstrated that the 
promoter regions of MuRF1 and MAFbx are hypomethylated during atrophy that corresponds with an 
increase in gene expression (Fisher et al., 2017), offering support for epigenetic alterations such as DNA 
methylation being inversely associated with gene expression of other E3 ubiquitin ligases such as UBR5. 
Furthermore, in the present dataset we provide further support for the alternate roles of UBR5 in comparison 
with MuRF1 and MAFbx during muscle loss. After 7 days of continuous low frequency electrical stimulation 
(20Hz) (13% muscle mass loss), MuRF1 and MAFbx were significantly increased while no significant 
increases were observed in UBR5 expression. Comparable results were obtained after 3 days of atrophy 
following nerve crush injury, whereby we observed significant increases in UBR5 gene expression that 
dropped back down at 7 days while MuRF1 and MAFbx remained elevated as muscle continued to waste at 
7-14 days. Together, this data supports a potential role for UBR5 in early remodelling after a wasting stimulus 
such as disuse or nerve silencing rather than in the extensive atrophy of muscle per se.  
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Because of its potential role in remodelling, we also looked to characterise UBR5 changes during recovery 
from atrophy as muscle mass returned towards pre-atrophy levels. Indeed, we demonstrated that after 7 days 
of recovery from TTX induced-atrophy, muscle mass was restored by approximately 52% and UBR5 was 
significantly hypomethylated and on average gene expression was upregulated while the other E3 ligases, 
MuRF1 and MAFbx were downregulated. While UBR5 gene expression just failed to reach significance (P = 
0.1), this was again interesting given the alternate regulation of UBR5 vs. MuRF1 and MAFbx gene 
expression. Furthermore, these data support other published observations where MuRF1/MAFbx have been 
shown not be unchanged in adult rats during recovery from atrophy induced by hindlimb unloading (Baehr et 
al., 2016). In the TTX model we only observed a partial 52% recovery of TA muscle mass over 7 days, yet 
saw a significant hypomethylation and average increase in UBR5 gene expression during recovery that might 
precede any later changes in protein abundance of UBR5. We therefore, measured UBR5 protein levels at 
later time points post recovery (14 d). Furthermore, due to limited sample from TTX atrophy recovery 
experiments for analysis of protein (as well as the muscle only being partially recovered 50% at 7 days upon 
termination of the experiments)  we measured protein abundance after atrophy and recovery from hindlimb 
unloading in rats in new analysis of already published samples, specifically in the medial gastrocnemius 
muscle that was fully recovered (Baehr et al., 2014). Firstly, we identified that protein levels increased at 3 
days following HU but returned to baseline by 14 days where most atrophy occurred, mirroring the temporal 
regulation observed at the gene expression level in the TTX atrophy model. This suggested that the HU 
model at the protein level presented a similar response to nerve silencing TTX-atrophy at the gene expression 
level. Importantly, after 3- and 14-days recovery from HU, we also observed a linear increase in UBR5 protein 
abundance, with the largest (approx. 50%) increase observed at 14 days where muscle mass was fully 
recovered. Additionally, there was a more rapid increase in aged muscle during recovery from atrophy at 3 
days peaking at an approx. 70% increase at 7 and 14 days during recovery, with these aged animals 
previously showing impaired recovery vs. young adult rats (Baehr et al., 2014). This suggests that an increase 
in protein abundance is important during full recovery in healthy young adults, but even a large and robust 
increase in UBR5 does not enable a full recovery of muscle mass in aged muscle. Finally, after recovery from 
nerve crush injury in mice, the protein abundance of UBR5 also increased significantly by 50% (similar 
increase after recovery from HU) and peaked at 28 and 45 days relating to a full recovery of muscle mass 
after 60 days. Overall, taken together across TTX atrophy, nerve crush and HU models, these data suggest 
that UBR5 is elevated in response to early atrophy and recovery and supports a role for this gene and protein 
in remodelling in adult and aged skeletal muscle tissue.  
 
Despite these interesting findings, it is worth mentioning that while UBR5 protein abundance significantly 
increased at 28 and 45 days following recovery from nerve crush in mice, opposed to the TTX model, UBR5 
gene expression did not change. While the reason for no change in mRNA versus increased protein 
abundance during recovery in the nerve crush model is not clear, it is worth mentioning that we analysed the 
gastrocnemius muscles because they recovered more over the time course versus the TA (data not shown). 
Whereas in the TTX model, UBR5 gene expression analysis was in the TA only (given the delivery of the 
TTX only silences TA and EDL, not gastrocnemius) and the TA is known to have a higher proportion of fast 
fibres. This discrepancy between gene expression and protein levels following nerve crush in the 
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gastrocnemius versus the other models, leads us to speculate that there are perhaps some important 
functions for UBR5 at the protein level across different fibre types. However, this requires further empirical 
evidence to support this hypothesis. Where future experiments should look to perform immunohistochemistry 
for UBR5 in muscles with different predominant fibre types. Indeed, a similar observation of no increase in 
gene expression but increases at the protein level occurred during human muscle cell differentiation. 
Previous studies have suggested UBR5 translocates into the nucleus in a complex that can silence 
transcription, for example in gene TRAF3 (Cho et al., 2017). However, UBR5 has also been shown to 
ubiquitinylate Groucho/TLE’s that are repressors of transcription and thus subsequently activate transcription 
of Armadillo/β-catenin (Flack et al., 2017). Furthermore, there is evidence that UBR5 can regulate 
translational machinery via interaction with CDK9 (Cojocaru et al., 2011) and PAIP2 (Yoshida et al., 2006). 
Therefore, this suggests that UBR5 localisation at the protein level, what it is binding to, what it ubiquitinates 
and its stability/ turnover would be an important avenue of future research in skeletal muscle atrophy and 
recovery from atrophy. This would be especially prudent in the nerve crush model, given the discrepancy in 
mRNA and protein data described above. Overall however, the atrophy and recovery data across models 
combined suggests that UBR5 is elevated early in atrophy and is reduced during later atrophy. Further, UBR5 
is elevated during recovery whereas MuRF1/MAFbx are downregulated. More work needs to determine the 
post-transcriptional regulation of UBR5, its localisation, substrates and binding complexes to further 
understand its mechanistic role in these processes.  
 
UBR5’s role in skeletal muscle anabolism and hypertrophy 
Given, UBR5’s elevations during early remodelling during atrophy and the subsequent recovery we also 
aimed to characterise its role in anabolism and hypertrophy. Indeed, the data in this manuscript suggests for 
the first time that increases in gene expression of the HECT domain E3 ligase, UBR5, occurred following 
acute loading of mouse bioengineered muscle in-vitro and after hypertrophy following chronic intermittent 
electrical stimulation in rats in-vivo. The increase in UBR5 gene expression after acute loading also occurred 
in the other E3 ligases, MuRF1 and MAFbx, however, after chronic-stimulation induced hypertrophy MuRF1 
and MAFbx did not increase whereas UBR5 increased. Together with the data above during atrophy and 
recovery, this data further supports that, at the gene expression level, UBR5 is alternately regulated versus 
MuRF1/MAFbx after hypertrophy, but interestingly after acute anabolic loading UBR5, MuRF1 and MAFbx 
all demonstrate an increase. This is perhaps not surprising given that MuRF1 and MAFbx/Atrogin-1 have 
also been shown to increase acutely after eccentric contractions in humans (Yang et al., 2006; Louis et al., 
2007). Furthermore, the increase in UBR5 gene expression after loading in bioengineered muscle (1.58 fold) 
supports our previous work in humans, demonstrating a similar fold change in UBR5 gene expression (1.71 
fold) after a single bout of resistance exercise in humans (Seaborne et al., 2018b). While gene expression 
was significantly elevated, the present study identified only 1 out of 6 CpG sites located in UBR5 promoter to 
be hypomethylated after acute loading in bioengineered muscle, however this was not significant. This 
supported our previous studies where there was no change in UBR5 DNA methylation after acute resistance 
exercise in humans (Seaborne et al., 2018b). Despite this, significant hypomethylation of UBR5 has been 
demonstrated to occur after repeated/chronic training and retraining induced hypertrophy in humans 
(Seaborne et al., 2018b) and in the present study hypertrophy (14% increase in mass) in rat muscle after 
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chronic intermittent electrical simulation evoked mean reductions in promoter UBR5 methylation 
(hypomethylation). However, in contrast with the aforementioned human study, the changes did not reach 
statistical significance. Currently, the data points towards repeated and chronic loading/exercise stimuli being 
required to cause promoter UBR5 hypomethylation, yet gene expression of UBR5 is elevated in response to 
both acute and chronic exercise stimuli. Also, given our previous work suggesting that hypomethylation of 
UBR5 is retained during detraining after a period of training induced atrophy, it is possible that once 
hypomethylation occurs it is relatively stable, and these changes can be retained over longer periods even 
when hypertrophic stimuli are removed. This hypothesis requires further investigation to be confirmed. 
 
In addition to significantly increased gene expression after acute anabolic and chronic hypertrophic stimuli in 
the present study, we also demonstrate that UBR5 protein abundance increased during human muscle cell 
differentiation and after hypertrophy in-vivo following synergist ablation (functional overload/FO) in mice. 
Indeed, during FO at first there was a significant decrease in UBR5 at 1 d, followed by a rapid and large 
increase at 3, 7 and 14 days corresponding with extensive hypertrophy of 65% increase in muscle mass by 
14 days. It is worth noting that while the initial significant reduction in UBR5 protein at 1d was initially 
surprising, in the same experiments and samples in earlier published studies at the gene expression level, 
MuRF1 and MAFbx mRNA were oppositely regulated (elevated) (Baehr et al., 2014), however were then 
downregulated at 3,7 and 14 days. This again suggesting that MuRF/MAFbx have alternate regulation 
compared to UBR5, as our other data confirms above across the different models of atrophy, recovery and 
hypertrophy. Overall, this is the first study to associate increases in protein abundance of UBR5 with 
differentiation and hypertrophy in skeletal muscle. Future studies should look to overexpress UBR5 in 
differentiating skeletal muscle cells and also in tissue in-vivo to confirm its role in hypertrophy. Furthermore, 
because UBR5 is an E3 ligase, with apparently alternate regulation to the more extensively studied MuRF1 
and MAFbx at the expression level, future studies should look to investigate its protein substrates. For 
example, studies in cancer cells have suggested that UBR5 can destabilise tumour suppressors such as 
MDM2/p53 by ubiquitination of upstream ribosomal protein L23 (RPL23), as well as tumour suppressor 
ECRG4, and its overexpression therefore enables growth and a reduction of apoptosis in colorectal cancer 
cells (Wang et al., 2017; Watanabe et al., 2018). Therefore, these interactions warrant further investigation 
in models of skeletal muscle anabolism and hypertrophy. Other studies also suggest that UBR5’s protein 
activity is important, due to phosphorylation by p90RSK (Cho et al., 2017) and MAPK1 (ERK2) in cells in 
response to epidermal growth factor (EGF) (Eblen et al., 2003), where ERK is a well-established regulator of 
muscle cell proliferation (Foulstone et al., 2004) and load-induced hypertrophy (Miyazaki et al., 2011) and 
p90RSK for protein synthesis in skeletal muscle tissue (Moore et al., 2011). Furthermore, in cancer, 
overexpression of UBR5 promotes tumour growth via destabilisation of PTEN (an inhibitor of PI3K/Akt) 
therefore allowing signalling via PI3K/AKT (Zhang et al., 2019), where PTEN and PI3K/Akt are key regulators 
of both muscle cell differentiation (Foulstone et al., 2004; Sharples et al., 2013) and muscle protein synthesis 
(reviewed in (Wackerhage et al., 2019)). Finally, UBR5 has been shown to destabilize p21 (Ji et al., 2017), 
where low p21 is associated with maintenance of muscle during periods of atrophy and high levels of p21 
associated with atrophy itself (Bongers et al., 2015). Therefore, UBR5 signalling (ERK, 
PTEN/PI3K/Akt/p90RSK), its targets (RPL23/p53, ECRG4, p21) and cellular location/transcription factor 
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binding (Groucho/TLE’s, TRAF3) will be key future avenues of research to uncover its mechanistic role in 
muscle cell differentiation and muscle hypertrophy.  
Finally, we investigated genetic variations of the UBR5 gene that were associated with UBR5 gene 
expression in humans using the online tool GTEx (Battle et al., 2017) to further corroborate the animal in vivo 
data, human in vitro data and previous in vivo human data (Seaborne et al., 2018b). Subsequently, the 
genetic variants that were identified were found significant in various human and athlete cohorts including 
physically active men, strength/power or endurance trained athletes. Indeed, we identified 2 SNPs, the first 
rs4734621 AA genotype (associated with increased UBR5 gene expression) was related to high competition 
results in elite weightlifters and the rs4734621 A allele was over-represented in both elite strength athletes 
versus controls and elite power athletes versus endurance athletes. Further, the A allele of the rs10505025 
polymorphism (which is strongly linked with rs4734621) was associated with greater CSA of fast-twitch 
muscle fibres in physically active men and was significantly over-represented in strength athletes and 
sprinters compared to endurance athletes. These genetic data support the animal data suggesting that where 
an increase in gene expression of UBR5 is expected that this is associated with hypertrophy. Furthermore, 
that adaptation to strength/resistance exercise and muscle size of fast fibres is associated with the 
aforementioned UBR5 polymorphisms in humans. The only study to date to investigate other E3 ligases 
polymorphisms and human muscle are studies in MuRF1 (rs2275950) that describe the AA homozygotes 
were stronger and demonstrate less muscle soreness in response to eccentric muscle damage compared 
with GG homozygotes (Baumert et al., 2018). At present no other studies have identified UBR5 
polymorphisms to be associated with skeletal muscle size and performance in humans. 
 
Conclusion 
Using multiple models of skeletal muscle atrophy/injury, recovery from atrophy, anabolism and hypertrophy 
in-vivo and in-vitro, we demonstrate for the first time that the E3 ubiquitin ligase UBR5, in alternate fashion 
to MuRF1/MAFbx at the gene expression level, is elevated during recovery, anabolism and hypertrophy in 
animals in-vivo as well as human muscle cell regeneration in-vitro. Finally, in humans the A alleles of the 
rs10505025 and rs4734621 SNPs that affect the expression of the UBR5 gene are strongly associated with 
larger fast-twitch muscle fibres and strength/power performance. 
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